Genentech Blood Cancer IP Not Double-Patented, Judge Rules
A California federal judge declined to invalidate two Genentech Inc. patents covering biotechnology used to make drugs for cancer and autoimmune diseases, ruling Thursday that Eli Lilly and Co.'s arguments that...To view the full article, register now.
Already a subscriber? Click here to view full article